J&J Hopes Eprex Experience Will Influence Follow-On Biologics Regulatory Pathway
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson is discussing its Eprex manufacturing complications in Europe with regulators working to develop a follow-on biologics pathway